Korean Medication Algorithm for Depressive Disorder: Comparisons with Other Treatment Guidelines
Hee Ryung Wang,Won-Myong Bahk,Young-Min Park,Hwang Bin Lee,Hoo Rim Song,Jong-Hyun Jeong,Jeong Seok Seo,Eunsung Lim,Jeongwan Hong,Won Kim,Duk-In Jon,Jin Pyo Hong,Young Sup Woo,Kyung Joon Min +13 more
TL;DR: The treatment recommendations of the Korean Medication Algorithm Project for Depressive Disorder 2012 are similar to those of other treatment guidelines and reflect current changes in prescription pattern for depression based on accumulated research data.
read more
Abstract: We aimed to compare the recommendations of the Korean Medication Algorithm Project for Depressive Disorder 2012 (KMAP-DD 2012) with other recently published treatment guidelines for depressive disorder. We reviewed a total of five recently published global treatment guidelines and compared each treatment recommendation of the KMAP-DD 2012 with those in other guidelines. For initial treatment recommendations, there were no significant major differences across guidelines. However, in the case of nonresponse or incomplete response to initial treatment, the second recommended treatment step varied across guidelines. For maintenance therapy, medication dose and duration differed among treatment guidelines. Further, there were several discrepancies in the recommendations for each subtype of depressive disorder across guidelines. For treatment in special populations, there were no significant differences in overall recommendations. This comparison identifies that, by and large, the treatment recommendations of the KMAP-DD 2012 are similar to those of other treatment guidelines and reflect current changes in prescription pattern for depression based on accumulated research data. Further studies will be needed to address several issues identified in our review.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Korean Medication Algorithm for Depressive Disorders 2017: Third Revision
Jeong Seok Seo,Won Myong Bahk,Hee Ryung Wang,Young Sup Woo,Young-Min Park,Jong-Hyun Jeong,Won Kim,Se Hoon Shim,Jung Goo Lee,Duk In Jon,Kyung Joon Min +10 more
TL;DR: The pharmacological treatment strategy in 2017 is similar to that of Korean Medication Algorithm for Depressive Disorder 2012, and the preference of AAPs was more increased.
45
Increased adrenocorticotropic hormone (ACTH) levels predict severity of depression after six months of follow-up in outpatients with major depressive disorder.
Kwan Woo Choi,Eun Jin Na,Maurizio Fava,David Mischoulon,Hana Cho,Hong Jin Jeon,Hong Jin Jeon +6 more
TL;DR: Increased ACTH level at baseline may predict ongoing symptoms and severity of depression at follow-up, suggesting the role of dysfunctional HPA axis in MDD prognosis.
38
Korean Medication Algorithm for Depressive Disorder: Comparisons with Other Treatment Guidelines.
Hee Ryung Wang,Won-Myong Bahk,Jeong Seok Seo,Young Sup Woo,Young-Min Park,Jong-Hyun Jeong,Won Kim,Se-Hoon Shim,Jung Goo Lee,Duk-In Jon,Kyung Joon Min +10 more
TL;DR: The KMAP-DD 2017 appeared to reflect current changes in the psychopharmacology of depression quite well, like other recently published evidence-based guidelines, although there were some differences between the guidelines.
21
Antidepressants and Mood Stabilizers: Novel Research Avenues and Clinical Insights for Bipolar Depression
TL;DR: Before treating MDEs, screening tools, specific symptom evaluation and medical history should be used to distinguish between bipolarity and mixed features in patients for whom AD monotherapy may present a risk.
21
Cost-effectiveness of vortioxetine versus venlafaxine (extended release) in the treatment of major depressive disorder in South Korea.
Sang-Eun Choi,M. Brignone,Seong Jin Cho,Hong Jin Jeon,Rangrhee Jung,R. Campbell,Clément François,Dominique Milea +7 more
TL;DR: Vortioxetine dominated venlafaxine XR in South Korea and is a relevant treatment option for MDD patients initiating or switching therapy, and remained dominant in 98% of probabilistic simulations.
12
References
Practice Parameter for the Assessment and Treatment of Children and Adolescents With Depressive Disorders
Boris Birmaher,David A. Brent,William Bernet,Oscar G. Bukstein,Heather J. Walter,R. Scott Benson,Allan K. Chrisman,Tiffany Farchione,Laurence L. Greenhill,John D. Hamilton,Helene Keable,Ulrich Schoettle,Saundra Stock,Kristin Kroeger Ptakowski,Jennifer Medicus,Amy Cheung,Greg Clarke,Graham J. Emslie,Philip Hazell,Stan Kutcher,Kelly Posner,Joseph M. Rey,Karen Dineen Wagner,Elizabeth B. Weller +23 more
TL;DR: This practice parameter describes the epidemiology, clinical picture, differential diagnosis, course, risk factors, and pharmacological and psychotherapy treatments of children and adolescents with major depressive or dysthymic disorders.
1K
Definition and epidemiology of treatment-resistant depression
TL;DR: Treatment-resistant depression patients can be defined as those who fail to respond to standard doses (i.e., significantly superior to placebo in double-blind studies) of antidepressants administered continuously for at least 6 weeks.
815
Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults
TL;DR: Some CAM treatments have evidence of benefit in MDD, however, problems with standardization and safety concerns may limit their applicability in clinical practice.
613
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care.
Michael Bauer,Tom Bschor,Andrea Pfennig,Peter C. Whybrow,Jules Angst,Marcio Versiani,Hans-Jürgen Möller,Wfsbp Task Force on Unipolar Depressive Disorders +7 more
TL;DR: These practical guidelines for the biological treatment of unipolar depressive disorders in primary care settings were developed by an international Task Force of the World Federation of Societies of Biological Psychiatry and offer practical recommendations for general practitioners encountering patients with these conditions.